Q-omics provides the consensus-scored RPS2P36 profile across patient tissues and cancer cell-line models. RPS2P36 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RPS2P36 is differentially expressed in 5, with the highest sampling consensus in KIRP. Additionally, RPS2P36 RNA expression shows 15,817 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight UCEC, KIRP, and DLBC as cancer lineages where RPS2P36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS2P36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS2P36 survival associations across molecular data types. RPS2P36 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS2P36 RNA expression–survival associations across cancer types. High RPS2P36 expression shows unfavorable associations in UCEC, THCA, READ, LUSC and UVM, but favorable associations in PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for RPS2P36 RNA expression.
This table summarizes RPS2P36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS2P36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS2P36 shows lower tumor expression in THCA and LUSC and higher tumor expression in KIRP, KIRC and STAD. The KIRP box plot shows higher RPS2P36 RNA expression in tumor versus normal tissue (log2 FC = +0.134, t-test p < 0.001).
This table shows molecular features associated with RPS2P36 in patient tissues and cancer cell lines. In patient samples, RPS2P36 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
